In the Phase 2b trials, this combination therapy achieved a 49% decrease in the risk of recurrence or death relative to ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

Moderna Inc (NASDAQ:MRNA) shares are trading higher on Wednesday on continued momentum after the company's Tuesday update ...

CHONGQING, CHINA - APRIL 26: In this photo illustration, the logo of Moderna, Inc. is displayed on a smartphone screen, with the company's branding visible in the background, on April 26, 2025, in ...

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...

Moderna's post-pandemic vaccine demand is weak, with mRESVIA unlikely to gain significant RSV market share due to commoditization and entrenched competitors. Financials remain strained: high costs, ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. This might not be enough to turn around the fortunes of the developer of go-to COVID-19 ...

The technical backdrop, however, points to caution. Seeking Alpha's momentum page flags Moderna as overbought on its relative strength index, with RSI levels indicating the stock has sprinted ahead of ...

Moderna, based in Cambridge, will lay off 10% of its workforce and expects “to be fewer than 5,000 colleagues strong” by the end of the year as part of its effort to cut costs. In a statement on ...

CAMBRIDGE, MA / ACCESS Newswire / December 15, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...

Moderna stock has dropped along with demand for a product that once drove tremendous growth: the coronavirus vaccine. Investors have remained focused on those declines -- and haven’t yet recognized ...